$29.570
+1.295 (+4.38%)At close
RAPP News
RAPP Events
Rapport Therapeutics Shares Drop 17.3%
Shares of Rapport Therapeutics (RAPP) were dropping after the company presented at TD Cowen's 6th Annual Novel Mechanisms in Neuropsychiatry Summit. Of note, CEO Abe Cassey said that he would "not be surprised" if some portion of patients in a trial of a bipolar mania treatment had "worsening mania symptoms," adding that bipolar mania could be a blockbuster plus "without a doubt." Shares of Rapport are down 17.3% in afternoon trading.
Rapport Reports Q1 Revenue of $20 Million
Reports Q1 revenue $20,000, consensus $6M. "We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials," said Abraham N. Ceesay, chief executive officer of Rapport. "With multiple important development milestones ahead, including continued advancement of our epilepsy franchise, progress in bipolar mania, and development of our long-acting injectable formulation, we believe we are well positioned to continue building value across our pipeline."
Rapport Therapeutics Announces RAP-219 Trial Results
Rapport Therapeutics announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures, FOS, in a late-breaker podium presentation at the 2026 American Academy of Neurology, AAN, Annual Meeting, taking place April 18-22, 2026 in Chicago. In the Phase 2a trial, patients received RAP-219 for 8 weeks and then entered an 8-week follow-up period after treatment ended to evaluate the effect of RAP-219 on long episodes and clinical seizures. Therapeutic levels of RAP-219 were sustained, resulting in continued biomarker and clinical responses in the 8-week follow-up period. In the first four weeks of follow-up, RAP-219 showed greater reductions in LEs and clinical seizures than were observed during the 8-week treatment period. Clinically meaningful improvements over baseline continued through the second four weeks of follow-up.
Trump Proposes Direct Talks Between Israel and Lebanon, Market Sentiment Improves
Reports that President Trump may be advocating for direct talks between Lebanon and Israeli negotiators to help preserve the Iranian ceasefire reversed the initial cautious sentiment in the markets on Thursday and helped the S&P 500 to notch its seventh consecutive gain. Consumer Cyclicals and Industrials sectors were the top performers on the session as Energy lagged once again, with WTI Crude Oil pricing heading back below $100 per barrel after briefly rising toward $103. The benchmark is now just over a percentage point away from the levels seen just prior to the strikes on Tehran in late February. Likewise, the Vix volatility gauge has moved back below the key 20-level, though the rally in Treasuries has stalled in the wake of this morning's PCE inflation report and ahead of Friday's CPI data.In addition to macro data developments, investors are hopeful that the geopolitical uncertainty will continue to clear as talks between Iranian and U.S. negotiators begin on Friday. Headlines from Thursday evening, however, suggest that there still may be some cause for concern - in a post on Truth Social, President Trump remarked that Iran is doing a "very poor job" on allowing oil through Hormuz. In the opening hour, S&P e-minis are down by a decimal below $68.60, with WTI prices also bouncing back toward the $100 mark.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Simulations Plusup 12.5%ALSO HIGHER -Cars.comup 2.2% after cutting headcount by 11%, affirming guidanceRapport Therapeuticsup 2.0% after being started at Strong Buy at Raymond JamesDOWN AFTER EARNINGS -Beam Globaldown 11.1%FGI Industries (down 9.2%WD-40 Companydown 0.5%
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.